Privacy preference
MEDtalks would like to keep you informed about the content that is most relevant to you. Click
here
for more information.
Yes
No
Back
Enfortumab vedotin plus pembrolizumab voor 1e lijns la/mUC: bijna 4 jaar follow-up!
Chat with us
, powered by
LiveChat